Crinetics Pharmaceuticals, Inc. (CRNX)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$115.1M
Cash & Equivalents
$124.7M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$8,846M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
PALTUSOTINE HYDROCHLORIDE
PALSONIFY |
APPROVED | Acromegaly, Carcinoid, Carcinoid Intestine Tumor, Carcinoid Syndrome, Carcinoid Syndrome Diarrhea, Carcinoid Tumor, Carcinoid Tumor of Cecum, Carcinoid Tumor of Ileum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Classic Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia, Cushing Disease, Cushing Syndrome, Ectopic ACTH Syndrome, Healthy Volunteers, Neuroendocrine Neoplasm, Neuroendocrine Tumors, SST2-positive Neuroendocrine Neoplasms |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-10-01 | Phase2 Readout | — |
| 2026-12-31 | Phase1 Readout | — |
| 2027-05-01 | Phase3 Readout | — |
Active Clinical Trials (9)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07144163 | A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | PHASE3 | Recruiting | 150 |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | PHASE3 | Recruiting | 141 |
| NCT07159841 | A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) | PHASE3 | Recruiting | 153 |
| NCT04837040 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly | PHASE3 | Active Not Recruiting | 58 |
| NCT07129252 | A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tu... | PHASE2 | Recruiting | 150 |
| NCT04261712 | A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) | PHASE2 | Active Not Recruiting | 43 |
| NCT05804669 | A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome | PHASE2 | Recruiting | 18 |
| NCT06712823 | An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia | PHASE2 | Recruiting | 200 |
| NCT07570082 | Drug-Drug Interaction Study of Atumelnant in Healthy Participants | PHASE1 | Active Not Recruiting | 46 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-06 | 8-K | Crinetics Pharmaceuticals, Inc. (CRNX) (CIK 0001658247) - EXHIBIT 99.1 | EDGAR |